Core Insights - The medical device sector is experiencing strong earnings and revenue growth driven by sustained demand for medical products and favorable pricing strategies, despite challenges from increased costs and geopolitical issues [1][2] Industry Overview - As of July 24, 16.9% of companies in the Medical sector, representing 33.8% of the sector's market capitalization, reported earnings, with 100% beating both earnings and revenue expectations [2] - The overall second-quarter earnings for the Medical sector are projected to improve by 19.4% with a 7.3% growth in revenues, contrasting with a 24% decline in earnings in the first quarter [2] Key Players and Performance - Major companies such as Labcorp, Bio-Rad, Teleflex, and Bruker are set to report their quarterly results, with expectations of varied performance based on market conditions [3][8] - Labcorp's second-quarter revenues are estimated at $3.20 billion, reflecting a 5.4% increase year-over-year, while EPS is expected to rise by 10.5% to $3.78 [9] - Bio-Rad anticipates a revenue decline of 4.8% to $648.6 million, with EPS expected to drop by 29.3% to $2.12 [11] - Teleflex's revenues are projected to reach $736.4 million, a 2.7% increase, while EPS is expected to decline by 2.4% to $3.33 [14] - Bruker is expected to report revenues of $796.2 million, indicating a 16.8% improvement, with EPS projected at 52 cents, a 4% increase [17] Market Trends and Challenges - The MedTech industry is witnessing rapid adoption of generative AI and digital therapies, which are anticipated to significantly impact healthcare [4] - Macro trends such as an aging population and increased healthcare awareness are expected to positively influence second-quarter results [5] - The industry faces challenges including staffing shortages, rising medical supply costs, and fluctuating demand for medical products as the healthcare system adjusts post-COVID-19 [6] - Diagnostic testing companies are experiencing a decline in testing demand compared to the previous year, particularly for COVID-19 testing products [7]

Simple Western instruments are fully automated, capillary western systems designed to resolve proteins based on molecular weight followed by immunodetection. Simple Western Systems replace traditional western blotting workflows by offering improvements in data quality and speed. The enhanced quantitation, reproducibility and throughput Leo now provides makes it possible for scientists to adopt western-based readouts in applications where westerns are not typically used due to inadequate reproducibility and ...

Investors might want to bet on Bio-Rad Laboratories (BIO) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. For Bio-Rad, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Harnessing the Power of ...

Core Insights - Bio-Techne Corporation has participated in Spear Bio's $45 million Series A funding round to accelerate product development and scale manufacturing capacity [1] - Spear Bio's ultra-sensitive detection technology offers significant advantages over traditional methods, enabling the quantification of low-abundance protein molecules, which is crucial for early diagnosis of neurodegenerative diseases [2][4] - The proprietary Successive Proximity Extension Amplification Reaction (SPEAR) technology allows for measuring protein biomarkers at attomolar levels from sub-microliter sample volumes, significantly reducing background noise compared to conventional assays [4][6] Company Overview - Bio-Techne Corporation is a global life sciences company that generated over $1.1 billion in net sales in fiscal 2023 and employs approximately 3,100 people worldwide [5] - Spear Bio, founded in 2021, focuses on developing ultra-sensitive immunoassays and is headquartered in Woburn, Massachusetts [4][6] - The collaboration between Bio-Techne and Spear Bio highlights the potential of SPEAR technology to transform protein research and early disease diagnosis [5]

Bio-Rad Laboratories, Inc.'s (BIO) growth in the upcoming quarters is likely to be backed by its Digital PCR business, which boasts a strong pipeline. The company's Clinical Diagnostics arm is seeing increased demand for quality control, blood typing and diabetes products. Sound financial stability also appears encouraging. However, the impact of macroeconomic challenges on Bio-Rad's operations poses a concern. Persistent reduced demand in the Biopharma segment adds to the worry. Let's delve deeper. Image S ...

Revenues of $610.8 million in the first quarter missed the Zacks Consensus Estimate by 0.2%. The figure dropped 9.8% from the year-ago quarter's levels (down 9.6% at the constant exchange rate or CER). VGM Scores The cumulative net cash flow from operating activities at the end of the first quarter was $697.9 million compared with the year-ago figure of $981.2 million. Bio-Rad belongs to the Zacks Medical - Products industry. Another stock from the same industry, Boston Scientific (BSX) , has gained 4.4% ov ...

About Bio-Techne Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. MINNEAPOLIS, May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the followi ...

AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with more than 18,500 industry leaders from across the globe. About Oncotelic For Oncotelic Therapeutics, Inc.: Investor Relations ir@oncotelic.com Oncot ...

Core Insights - Bio-Techne Corporation will showcase its MauriceFlex™ System at the 72nd ASMS Conference, highlighting its capabilities in protein characterization and charge variant fractionation [1][4] - The MauriceFlex system simplifies the process of charge variant fraction collection, enhancing downstream protein characterization using various mass spectrometric methods [1][4] Product Features - The MauriceFlex system is an imaged capillary isoelectric focusing (icIEF) solution that supports icIEF-based fractionation and routine assays [1] - It enables the fractionation of charge isoforms in monoclonal antibodies and AAV capsid proteins, making it suitable for applications in cell and gene therapy [2][3] Conference Activities - A breakfast seminar titled "Solving the Challenges of Protein Charge Heterogeneity Characterization using icIEF" will be held on June 4th, featuring insights from Bio-Techne and the National Institute for Bioprocessing Research and Training [2] - Bio-Techne will present seven posters at the conference, detailing collaborations with industry partners like Pfizer and advancements in charge isoform characterization [3] Company Overview - Bio-Techne Corporation is a global life sciences company with over $1.1 billion in net sales for fiscal 2023 and approximately 3,100 employees [5] - The company provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding in drug discovery and accurate clinical tests [5]

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [3] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [3] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product for Gaucher disease, to Pfizer Inc., retaining full rights in Brazil [3] Product Pipeline - Protalix's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [3] - The company has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [4] - The development pipeline includes PRX–115, a recombinant PEGylated uricase for uncontrolled gout, and PRX–119, a long-acting DNase I for NETs-related diseases, among others [4] Industry Context - The BIO International Convention is the largest industry gathering for biotechnology and biopharmaceutical leaders, providing networking and partnering opportunities [2][5] - The event will take place from June 3-6, 2024, in San Diego, California, where Protalix's CEO will present corporate updates [1]